InvestorsHub Logo
Followers 167
Posts 13551
Boards Moderated 1
Alias Born 01/26/2016

Re: skitahoe post# 248333

Sunday, 10/20/2019 9:00:11 PM

Sunday, October 20, 2019 9:00:11 PM

Post# of 720881
skitahoe,

Validation of L and an "appraisal" of Direct by Mr. Duffy coupled with commercial readiness for both products either currently or very shortly ready with a chance to move quickly to label extensions is a much different scenario than what you are comparing against with Kite which still carried major issues with it going forward when bought. Anyone who does not understand this will be bought out on the cheap because they do not understand the potential speed at which these NWBO treatments can advance into approvals especially if a rolling BLA has been ongoing. I believe Dr. Duffy is assessing this potential right now. Just seeing the SAP comparing blinded and unblinded results from other sources would give him a very good basis for drawing some conclusions. There is a reason why preferred stock was converted almost 1 year ago, 4 year data is available in 3 weeks, Cognate is amped up, only treatment patients were enrolled after the halt and Dr. Duffy is in the house. Linearly directed convergence of Donald, Daffy and like birds of a feather and those guys have agents that won't settle for $1 or $2. Leverage. Best wishes.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News